Investigational Drug Information for Valopicitabine
✉ Email this page to a colleague
What is the development status for investigational drug Valopicitabine?
Valopicitabine is an investigational drug.
There have been 4 clinical trials for Valopicitabine.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2005.
The most common disease conditions in clinical trials are Hepatitis, Chronic, Hepatitis C, Chronic, and Hepatitis C. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Novartis Pharmaceuticals, and [disabled in preview].
Summary for Valopicitabine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 567 |
| WIPO Patent Applications | 340 |
| Japanese Patent Applications | 220 |
| Clinical Trial Progress | Phase 2 (2005-08-01) |
| Vendors | 15 |
Recent Clinical Trials for Valopicitabine
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin | Novartis Pharmaceuticals | Phase 2 |
| Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin | Merck Sharp & Dohme Corp. | Phase 2 |
| A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C | Merck Sharp & Dohme Corp. | Phase 2 |
Clinical Trial Summary for Valopicitabine
Top disease conditions for Valopicitabine
Top clinical trial sponsors for Valopicitabine
US Patents for Valopicitabine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
